← Back to All Filings

Cytokinetics Director Sells $257K in Stock via 10b5-1 Plan

Low SignificanceOctober 27, 2025 at 6:02:08 PM EDT

CYTOKINETICS INC

$CYTK4CIK: 0001061983

Subscribe to track CYTK

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Cytokinetics Director Sells $257K in Stock via 10b5-1 Plan

Company: CYTOKINETICS INC (CYTK) Form: 4 | Filed: 2025-10-27 Significance: Low

Insider: WIERENGA WENDELL Title: null | Relationship: Director

Transaction: • Type: Sell (following option exercise) • Shares: 4,375 • Price: $58.68 • Value: $256,725 • Owned After: 32,444

Key Insight: This was a pre-planned sale under a 10b5-1 trading plan, initiated after exercising stock options. Such transactions are common for insiders and typically have low signaling value.

Market Context: The sale represents a negligible fraction (0.0037%) of Cytokinetics' $6.92B market cap, making it immaterial to the company's overall valuation.

Comprehensive Analysis

SEC Filing Analysis: CYTOKINETICS INC (CYTK)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: A director executed a routine, pre-planned "exercise and sell" of stock options under a 10b5-1 plan, a transaction with minimal market signaling value.
  • Market Impact: The transaction's value is immaterial compared to the company's multi-billion dollar market capitalization, suggesting a neutral market impact.

Company Information

FieldValue
CompanyCYTOKINETICS INC
Ticker SymbolCYTK
CIK0001061983
IndustryPHARMACEUTICAL PREPARATIONS [2834]

Insider Information

FieldValue
NameWIERENGA WENDELL
CIK0001239956
Title/Positionnull
RelationshipDirector

Transaction Details

This filing reports a 'cashless exercise' where options were exercised and the resulting shares were immediately sold. The primary market-facing event is the sale.

FieldValue
Form Type4
Transaction Date2025-10-27
Transaction CodeS (Sale) / M (Option Exercise)
Security TypeCommon Stock
Shares Involved4,375
Price Per Share$58.68 (Sale) / $10.00 (Exercise)
Total Value$256,725 (Sale)
Shares Owned After32,444
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$256,725
% of Market Cap0.0037%
Shares Transacted4,375
% of Shares Outstanding0.0037%
Post-Transaction Ownership32,444 shares (0.027% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $6.92 billion, a transaction valued at $256,725 is financially insignificant.
  • Ownership Concentration: The insider's post-transaction ownership of 0.027% is not a controlling stake. The sale of 4,375 shares reduced the insider's holdings by approximately 11.9%, which is not a substantial liquidation of their position.
  • Dilution Impact: The transaction involved the exercise of existing options, not the issuance of new ones. The potential dilution was already factored into the company's fully diluted share count. The net effect on shares outstanding is neutral as the exercised shares were immediately sold into the market.
  • Transaction Significance: The sale represents less than 0.01% of both the company's market cap and its shares outstanding. These figures are well below the thresholds for even moderate significance, categorizing this as a routine, low-impact event.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The sale was conducted under a pre-scheduled 10b5-1 plan, which negates the assumption that it was timed based on non-public information. The small size of the transaction relative to the company's market cap and daily trading volume is unlikely to influence the stock price.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The 4,375 shares sold would likely be absorbed by the market without a noticeable impact on trading volume.
  • Sentiment Indicator: Neutral. Informed investors typically disregard small, pre-planned 10b5-1 sales as they are common for executive compensation and portfolio management, not as a bearish signal.

Investment Insights

Positive Market Indicators

  • The insider still retains a position of 32,444 shares, valued at over $1.9 million at the sale price, indicating continued alignment with shareholder interests.

Risk Factors

  • No significant risk factors are indicated by this specific filing.

Key Takeaways

  1. Routine Transaction: This is a standard 'exercise-and-sell' transaction, common for insiders to realize value from stock options.
  2. 10b5-1 Plan: The sale was pre-planned, which significantly diminishes its value as a real-time indicator of insider sentiment.
  3. Immaterial Size: The transaction's value is a tiny fraction of the company's market capitalization, making it financially insignificant from a market perspective.

Additional Context

Transaction Notes

  • Special Circumstances: The filing explicitly notes this was a transaction made pursuant to a Rule 10b5-1 trading plan. The insider exercised options that were set to expire in early 2026.
  • Market Environment: This type of transaction is common for insiders regardless of the broader market environment, as it is often tied to personal financial planning or tax obligations.
Topics:#SECFiling#InsiderTrading#CYTK#Cytokinetics#Form4#InsiderSell#StockMarket#Investing#10b51

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.